New MS drug shows promise in reducing brain damage
NCT ID NCT05119569
Summary
This study is testing whether an experimental drug called fenebrutinib can reduce brain inflammation in people with relapsing multiple sclerosis. About 109 participants will receive either fenebrutinib or a placebo for 12 weeks, with researchers using brain scans to measure changes in lesions. The main goal is to see if the drug slows the formation of new brain lesions, which are markers of MS activity.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic Lou Ruvo
Las Vegas, Nevada, 89106, United States
-
Clinical Center Nis
Niš, 18000, Serbia
-
Clinical Center of Serbia
Belgrade, 11000, Serbia
-
Clinical Hospital Center Rijeka - PPDS
Rijeka, 51000, Croatia
-
Clinical Hospital Centre Zemun
Zemun, 11080, Serbia
-
Clinical center Kragujevac
Kragujevac, 34000, Serbia
-
Fakultni nemocnice Hradec Kralove
Hradec Králové, 500 05, Czechia
-
Fakultni nemocnice u sv. Anny v Brne
Brno, 656 91, Czechia
-
Fullerton Neurology and Headache Center
Fullerton, California, 92835, United States
-
General Hospital Varazdin
Varaždin, 42000, Croatia
-
Klinicki bolnicki centar Zagreb
Zagreb, 10000, Croatia
-
Military Medical Academy
Belgrade, 11040, Serbia
-
Nemocnice Jihlava
Jihlava, 58633, Czechia
-
Poliklinika Solmed
Zagreb, 10000, Croatia
-
University Clinical Centre of the Republic of Srpska
Banja Luka, 78000, Bosnia and Herzegovina
-
Univerzitna nemocnica Bratislava
Bratislava, 821 01, Slovakia
-
Vseobecna Fakultni Nemocnice V Praze - CRC - PPDS
Prague, 128 08, Czechia
Conditions
Explore the condition pages connected to this study.